{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:50:40Z","timestamp":1793659840105,"version":"4.5.1"},"reference-count":192,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Graduate Research Innovation Project in Jiangsu province","award":["[No.SJCX21_1644]"],"award-info":[{"award-number":["[No.SJCX21_1644]"]}]},{"name":"the Academic Science and Technology Innovation Fund for College Students","award":["[No. 202011117056Y]"],"award-info":[{"award-number":["[No. 202011117056Y]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1245\/s10434-025-17368-9","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T13:32:14Z","timestamp":1747143134000},"page":"6080-6097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["ncRNAs as Key Regulators in Gastric Cancer: From Molecular Subtyping to Therapeutic Targets"],"prefix":"10.1245","volume":"32","author":[{"given":"Chen","family":"Gu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenni","family":"ChenLiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"17368_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"17368_CR2","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.gendis.2021.02.002","volume":"9","author":"SK Sagar","year":"2022","unstructured":"Sagar SK. miR-106b as an emerging therapeutic target in cancer. Genes Dis. 2022;9:889\u201399.","journal-title":"Genes Dis."},{"key":"17368_CR3","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-018-1510-y","volume":"16","author":"Q Peng","year":"2018","unstructured":"Peng Q, et al. Comprehensive and integrative analysis identifies microRNA-106 as a novel non-invasive biomarker for detection of gastric cancer. J Transl Med. 2018;16:127.","journal-title":"J Transl Med."},{"key":"17368_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121667","volume":"322","author":"D Fathi","year":"2023","unstructured":"Fathi D, et al. An emphasis on the interaction of signaling pathways highlights the role of miRNAs in the etiology and treatment resistance of gastric cancer. Life Sci. 2023;322:121667.","journal-title":"Life Sci."},{"key":"17368_CR5","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14737159.2022.2159381","volume":"22","author":"F Sogutlu","year":"2022","unstructured":"Sogutlu F, Pekerbas M, Biray Avci C. Epigenetic signatures in gastric cancer: current knowledge and future perspectives. Expert Rev Mol Diagn. 2022;22:1063\u201375.","journal-title":"Expert Rev Mol Diagn."},{"key":"17368_CR6","doi-asserted-by":"crossref","unstructured":"Lupan I, et al. Epigenetic regulation of DNA methylation and RNA interference in gastric cancer: a 2024 update. Biomedicines. 2024;12(9):2001.","DOI":"10.3390\/biomedicines12092001"},{"key":"17368_CR7","doi-asserted-by":"crossref","unstructured":"Bakinowska E, et al. Non-coding RNA as biomarkers and their role in the pathogenesis of gastric cancer: a narrative review. Int J Mol Sci. 2024;25(10):5144.","DOI":"10.3390\/ijms25105144"},{"key":"17368_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/EBC20200032","volume":"65","author":"H Yan","year":"2021","unstructured":"Yan H, Bu P. Non-coding RNA in cancer. Essays Biochem. 2021;65:625\u201339.","journal-title":"Essays Biochem."},{"key":"17368_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ncrna.2016.12.001","volume":"1","author":"A Ahmad","year":"2016","unstructured":"Ahmad A. Non-coding RNAs: a tale of junk turning into treasure. Noncoding RNA Res. 2016;1:1\u20132.","journal-title":"Noncoding RNA Res."},{"key":"17368_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.tig.2014.08.004","volume":"30","author":"A Kapusta","year":"2014","unstructured":"Kapusta A, Feschotte C. Volatile evolution of long noncoding RNA repertoires: mechanisms and biological implications. Trends Genet. 2014;30:439\u201352.","journal-title":"Trends Genet."},{"key":"17368_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cbf.4018","volume":"42","author":"D Darmadi","year":"2024","unstructured":"Darmadi D, et al. Critical roles of long noncoding RNA H19 in cancer. Cell Biochem Funct. 2024;42:e4018.","journal-title":"Cell Biochem Funct."},{"key":"17368_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117368","volume":"179","author":"M Vaghari-Tabari","year":"2024","unstructured":"Vaghari-Tabari M, Qujeq D, Hashemzadeh MS. Long noncoding RNAs as potential targets for overcoming chemoresistance in upper gastrointestinal cancers. Biomed Pharmacother. 2024;179:117368.","journal-title":"Biomed Pharmacother."},{"key":"17368_CR13","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.trecan.2024.06.007","volume":"10","author":"TR de Back","year":"2024","unstructured":"de Back TR, et al. Transcriptomic subtyping of gastrointestinal malignancies. Trends Cancer. 2024;10:842\u201356.","journal-title":"Trends Cancer."},{"key":"17368_CR14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","volume":"145","author":"Z Lei","year":"2013","unstructured":"Lei Z, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145:554\u201365.","journal-title":"Gastroenterology."},{"key":"17368_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/his.13975","volume":"76","author":"ID Nagtegaal","year":"2020","unstructured":"Nagtegaal ID, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182\u20138.","journal-title":"Histopathology."},{"key":"17368_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apm.1965.64.1.31","volume":"64","author":"P Lauren","year":"1965","unstructured":"Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma: an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31\u201349.","journal-title":"Acta Pathol Microbiol Scand."},{"key":"17368_CR17","doi-asserted-by":"crossref","unstructured":"Ma Y, et al. Current development of molecular classifications of gastric cancer based on omics (review). Int J Oncol. 2024;65(3):89.","DOI":"10.3892\/ijo.2024.5677"},{"key":"17368_CR18","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Comprehensive molecular characterization of gastric adenocarcinoma","year":"2014","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature."},{"key":"17368_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000473881","volume":"85","author":"I Gullo","year":"2018","unstructured":"Gullo I, et al. Heterogeneity in gastric cancer: from pure morphology to molecular classifications. Pathobiology. 2018;85:50\u201363.","journal-title":"Pathobiology."},{"key":"17368_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","volume":"18","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, et al. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021;18:473\u201387.","journal-title":"Nat Rev Clin Oncol."},{"key":"17368_CR21","doi-asserted-by":"crossref","unstructured":"Salnikov M, et al. Tumor-infiltrating T cells in EBV-associated gastric carcinomas exhibit high levels of multiple markers of activation, effector gene expression, and exhaustion. Viruses. 2023;15(1):176.","DOI":"10.3390\/v15010176"},{"key":"17368_CR22","doi-asserted-by":"publisher","first-page":"1938381","DOI":"10.1080\/2162402X.2021.1938381","volume":"10","author":"XL Wei","year":"2021","unstructured":"Wei XL, et al. The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. Oncoimmunology. 2021;10:1938381.","journal-title":"Oncoimmunology."},{"key":"17368_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20:407\u201315.","journal-title":"Gastric Cancer."},{"key":"17368_CR24","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392\u2013400.","journal-title":"J Clin Oncol."},{"key":"17368_CR25","doi-asserted-by":"crossref","unstructured":"Randon G, et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. 2023;11(6):e007104.","DOI":"10.1136\/jitc-2023-007104"},{"key":"17368_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102175","volume":"95","author":"E Puliga","year":"2021","unstructured":"Puliga E, et al. Microsatellite instability in gastric cancer: between lights and shadows. Cancer Treat Rev. 2021;95:102175.","journal-title":"Cancer Treat Rev."},{"key":"17368_CR27","doi-asserted-by":"crossref","unstructured":"Perez-Wert P, et al. Layer analysis based on RNA-seq reveals molecular complexity of gastric cancer. Int J Mol Sci. 2024;25(21):11371.","DOI":"10.3390\/ijms252111371"},{"key":"17368_CR28","doi-asserted-by":"crossref","unstructured":"Zheng S, Guerrero-Haughton E, Foijer F. Chromosomal instability-driven cancer progression: interplay with the tumour microenvironment and therapeutic strategies. Cells. 2023;12(23):2712.","DOI":"10.3390\/cells12232712"},{"key":"17368_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.trecan.2024.03.008","volume":"10","author":"T Yasuda","year":"2024","unstructured":"Yasuda T, Wang YA. Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development. Trends Cancer. 2024;10:627\u201342.","journal-title":"Trends Cancer."},{"key":"17368_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.neo.2017.02.012","volume":"19","author":"SS Maleki","year":"2017","unstructured":"Maleki SS, R\u00f6cken C. Chromosomal instability in gastric cancer biology. Neoplasia. 2017;19:412\u201320.","journal-title":"Neoplasia."},{"key":"17368_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"Pan-cancer analysis of whole genomes","year":"2020","unstructured":"Pan-cancer analysis of whole genomes. Nature. 2020;578:82\u201393.","journal-title":"Nature."},{"key":"17368_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/pin.13427","volume":"74","author":"T Kuwata","year":"2024","unstructured":"Kuwata T. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathol Int. 2024;74:301\u201316.","journal-title":"Pathol Int."},{"key":"17368_CR33","doi-asserted-by":"publisher","first-page":"6457","DOI":"10.1002\/jcp.30320","volume":"236","author":"X Zhou","year":"2021","unstructured":"Zhou X, et al. Epstein-Barr virus (EBV) encoded microRNA BART8-3p drives radioresistance-associated metastasis in nasopharyngeal carcinoma. J Cell Physiol. 2021;236:6457\u201371.","journal-title":"J Cell Physiol."},{"key":"17368_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.7150\/ijbs.30099","volume":"15","author":"K Min","year":"2019","unstructured":"Min K, Lee SK. EBV miR-BART10-3p promotes cell proliferation and migration by targeting DKK1. Int J Biol Sci. 2019;15:657\u201367.","journal-title":"Int J Biol Sci."},{"key":"17368_CR35","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12985-020-01308-y","volume":"17","author":"J Zhang","year":"2020","unstructured":"Zhang J, et al. Long noncoding RNAs involvement in Epstein-Barr virus infection and tumorigenesis. Virol J. 2020;17:51.","journal-title":"Virol J."},{"key":"17368_CR36","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12935-021-01986-w","volume":"21","author":"Y Liu","year":"2021","unstructured":"Liu Y, et al. Long non-coding RNAs in Epstein-Barr virus-related cancer. Cancer Cell Int. 2021;21:278.","journal-title":"Cancer Cell Int."},{"key":"17368_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111622","volume":"139","author":"X Yuan","year":"2021","unstructured":"Yuan X, Yan Y, Xue M. Small nucleolar RNA host gene 8: a rising star in the targets for cancer therapy. Biomed Pharmacother. 2021;139:111622.","journal-title":"Biomed Pharmacother."},{"key":"17368_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s10120-024-01523-4","volume":"27","author":"A Ooki","year":"2024","unstructured":"Ooki A, et al. Potent therapeutic strategy in gastric cancer with microsatellite instability-high and\/or deficient mismatch repair. Gastric Cancer. 2024;27:907\u201331.","journal-title":"Gastric Cancer."},{"key":"17368_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.933475","volume":"13","author":"S Han","year":"2022","unstructured":"Han S, et al. The distinct clinical trajectory, metastatic sites, and immunobiology of microsatellite-instability-high cancers. Front Genet. 2022;13:933475.","journal-title":"Front Genet."},{"key":"17368_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/modpathol.2016.73","volume":"29","author":"ML Slattery","year":"2016","unstructured":"Slattery ML, et al. Colorectal tumor molecular phenotype and miRNA: expression profiles and prognosis. Mod Pathol. 2016;29:915\u201327.","journal-title":"Mod Pathol."},{"key":"17368_CR41","doi-asserted-by":"crossref","unstructured":"Randrian V, Evrard C, Tougeron D. Microsatellite instability in colorectal cancers: carcinogenesis, neo-antigens, immuno-resistance and emerging therapies. Cancers Basel. 2021;13(12):3063.","DOI":"10.3390\/cancers13123063"},{"key":"17368_CR42","first-page":"1299","volume":"44","author":"Y Lei","year":"2020","unstructured":"Lei Y, et al. MicroRNAs target the Wnt\/\u03b2-catenin signaling pathway to regulate epithelial-mesenchymal transition in cancer (review). Oncol Rep. 2020;44:1299\u2013313.","journal-title":"Oncol Rep."},{"key":"17368_CR43","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cell.2011.07.014","volume":"146","author":"L Salmena","year":"2011","unstructured":"Salmena L, et al. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? Cell. 2011;146:353\u20138.","journal-title":"Cell."},{"key":"17368_CR44","doi-asserted-by":"crossref","unstructured":"Nemtsova MV, Kuznetsova EB, Bure IV. Chromosomal instability in gastric cancer: role in tumor development, progression, and therapy. Int J Mol Sci. 2023;24(23):16961.","DOI":"10.3390\/ijms242316961"},{"key":"17368_CR45","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3892\/ol.2021.12818","volume":"22","author":"P Gong","year":"2021","unstructured":"Gong P, et al. Upregulation of LINC00659 expression predicts a poor prognosis and promotes migration and invasion of gastric cancer cells. Oncol Lett. 2021;22:557.","journal-title":"Oncol Lett."},{"key":"17368_CR46","doi-asserted-by":"publisher","first-page":"1039366","DOI":"10.3389\/fonc.2022.1039366","volume":"12","author":"Q Xia","year":"2022","unstructured":"Xia Q, et al. LINC00324 in cancer: Regulatory and therapeutic implications. Front Oncol. 2022;12:1039366.","journal-title":"Front Oncol."},{"key":"17368_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.omtn.2020.10.022","volume":"22","author":"ZH Ma","year":"2020","unstructured":"Ma ZH, et al. BTEB2-activated lncRNA TSPEAR-AS2 drives GC progression through suppressing GJA1 expression and upregulating CLDN4 expression. Mol Ther Nucleic Acids. 2020;22:1129\u201341.","journal-title":"Mol Ther Nucleic Acids."},{"key":"17368_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.placenta.2024.05.135","volume":"153","author":"S Selvakumar","year":"2024","unstructured":"Selvakumar S, Preethi KA, Sekar D. MicroRNA-510-3p regulated vascular dysfunction in preeclampsia by targeting vascular endothelial growth factor A (VEGFA) and its signaling axis. Placenta. 2024;153:31\u201352.","journal-title":"Placenta."},{"key":"17368_CR49","doi-asserted-by":"publisher","first-page":"326","DOI":"10.23736\/S2724-6329.23.04824-6","volume":"72","author":"FF Anees","year":"2023","unstructured":"Anees FF, et al. Prospective study: expression levels of microRNA-7-3p and its target STAT3 in head and neck cancer. Minerva Dent Oral Sci. 2023;72:326\u201331.","journal-title":"Minerva Dent Oral Sci."},{"key":"17368_CR50","doi-asserted-by":"crossref","unstructured":"Ashrafizadeh M, et al. MicroRNAs and their influence on the ZEB family: mechanistic aspects and therapeutic applications in cancer therapy. Biomolecules. 2020;10(7):104.","DOI":"10.3390\/biom10071040"},{"key":"17368_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173660","volume":"892","author":"M Ashrafizadeh","year":"2021","unstructured":"Ashrafizadeh M, et al. MicroRNA-mediated autophagy regulation in cancer therapy: the role in chemoresistance\/chemosensitivity. Eur J Pharmacol. 2021;892:173660.","journal-title":"Eur J Pharmacol."},{"key":"17368_CR52","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1111\/cas.13965","volume":"110","author":"RU Takahashi","year":"2019","unstructured":"Takahashi RU, et al. Development of miRNA-based therapeutic approaches for cancer patients. Cancer Sci. 2019;110:1140\u20137.","journal-title":"Cancer Sci."},{"key":"17368_CR53","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3892\/or.2014.3052","volume":"31","author":"J Xie","year":"2014","unstructured":"Xie J, et al. miR-7 inhibits the invasion and metastasis of gastric cancer cells by suppressing epidermal growth factor receptor expression. Oncol Rep. 2014;31:1715\u201322.","journal-title":"Oncol Rep."},{"key":"17368_CR54","doi-asserted-by":"crossref","unstructured":"Tse J, et al. Onco-miR-21 promotes stat3-dependent gastric cancer progression. Cancers Basel. 2022;14(2):264.","DOI":"10.3390\/cancers14020264"},{"key":"17368_CR55","doi-asserted-by":"crossref","unstructured":"Zhao X, et al. Interferon\u2011stimulated gene 15 promotes progression of endometrial carcinoma and weakens antitumor immune response. Oncol Rep. 2022;47(6):110.","DOI":"10.3892\/or.2022.8321"},{"key":"17368_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144453","volume":"738","author":"S Najjary","year":"2020","unstructured":"Najjary S, et al. Role of miR-21 as an authentic oncogene in mediating drug resistance in breast cancer. Gene. 2020;738:144453.","journal-title":"Gene."},{"key":"17368_CR57","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/labinvest.2008.94","volume":"88","author":"Z Zhang","year":"2008","unstructured":"Zhang Z, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest. 2008;88:1358\u201366.","journal-title":"Lab Invest."},{"key":"17368_CR58","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41241-017-0045-5","volume":"37","author":"AA Bahnassy","year":"2017","unstructured":"Bahnassy AA, et al. Aberrant expression of miRNAs predicts recurrence and survival in stage-II colorectal cancer patients from Egypt. Appl Cancer Res. 2017;37:39.","journal-title":"Appl Cancer Res."},{"key":"17368_CR59","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/cncr.27895","volume":"119","author":"Y Tanaka","year":"2013","unstructured":"Tanaka Y, et al. Clinical impact of serum exosomal microRNA-21 as a clinical biomarker in human esophageal squamous cell carcinoma. Cancer. 2013;119:1159\u201367.","journal-title":"Cancer."},{"key":"17368_CR60","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/07357907.2011.568562","volume":"29","author":"HJ Song","year":"2011","unstructured":"Song HJ, et al. 15-hydroxyprostaglandin dehydrogenase is downregulated and exhibits tumor suppressor activity in gastric cancer. Cancer Invest. 2011;29:257\u201365.","journal-title":"Cancer Invest."},{"key":"17368_CR61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3892\/or.2012.1645","volume":"27","author":"BG Zhang","year":"2012","unstructured":"Zhang BG, et al. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 2012;27:1019\u201326.","journal-title":"Oncol Rep."},{"key":"17368_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121340","volume":"316","author":"B Farasati Far","year":"2023","unstructured":"Farasati Far B, et al. The role of microRNA-21 (miR-21) in pathogenesis, diagnosis, and prognosis of gastrointestinal cancers: a review. Life Sci. 2023;316:121340.","journal-title":"Life Sci."},{"key":"17368_CR63","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/labinvest.2014.125","volume":"94","author":"D Yu","year":"2014","unstructured":"Yu D, et al. miR-106b modulates cancer stem cell characteristics through TGF-\u03b2\/Smad signaling in CD44-positive gastric cancer cells. Lab Invest. 2014;94:1370\u201381.","journal-title":"Lab Invest."},{"key":"17368_CR64","doi-asserted-by":"publisher","first-page":"606","DOI":"10.33594\/000000043","volume":"52","author":"Z Zhu","year":"2019","unstructured":"Zhu Z, et al. miR-106b promotes metastasis of early gastric cancer by targeting ALEX1 in vitro and in vivo. Cell Physiol Biochem. 2019;52:606\u201316.","journal-title":"Cell Physiol Biochem."},{"key":"17368_CR65","doi-asserted-by":"publisher","first-page":"101042831770165","DOI":"10.1177\/1010428317701652","volume":"39","author":"N Jafari","year":"2017","unstructured":"Jafari N, Abediankenari S. MicroRNA-34 dysregulation in gastric cancer and gastric cancer stem cell. Tumour Biol. 2017;39:1010428317701652.","journal-title":"Tumour Biol."},{"key":"17368_CR66","doi-asserted-by":"publisher","first-page":"23772","DOI":"10.1038\/srep23772","volume":"6","author":"H Liang","year":"2016","unstructured":"Liang H, et al. miR-93 functions as an oncomiR for the downregulation of PDCD4 in gastric carcinoma. Sci Rep. 2016;6:23772.","journal-title":"Sci Rep."},{"key":"17368_CR67","doi-asserted-by":"publisher","first-page":"12342","DOI":"10.1038\/s41598-020-69308-0","volume":"10","author":"N Jafari","year":"2020","unstructured":"Jafari N, et al. Expression patterns of seven key genes, including \u03b2-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer. Sci Rep. 2020;10:12342.","journal-title":"Sci Rep."},{"key":"17368_CR68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semcancer.2024.06.001","volume":"102\u2013103","author":"CP Bracken","year":"2024","unstructured":"Bracken CP, Goodall GJ. Gregory PA RNA regulatory mechanisms controlling TGF-\u03b2 signaling and EMT in cancer. Semin Cancer Biol. 2024;102\u2013103:4\u201316.","journal-title":"Semin Cancer Biol."},{"key":"17368_CR69","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1084\/jem.20181827","volume":"216","author":"NM Aiello","year":"2019","unstructured":"Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. J Exp Med. 2019;216:1016\u201326.","journal-title":"J Exp Med."},{"key":"17368_CR70","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.devcel.2021.02.028","volume":"56","author":"Y Katsuno","year":"2021","unstructured":"Katsuno Y, Derynck R. Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-\u03b2 family. Dev Cell. 2021;56:726\u201346.","journal-title":"Dev Cell."},{"key":"17368_CR71","doi-asserted-by":"publisher","first-page":"66989","DOI":"10.18632\/oncotarget.11888","volume":"7","author":"C Li","year":"2016","unstructured":"Li C, et al. MicroRNA-21 promotes TGF-\u03b21-induced epithelial-mesenchymal transition in gastric cancer through up-regulating PTEN expression. Oncotarget. 2016;7:66989\u20137003.","journal-title":"Oncotarget."},{"key":"17368_CR72","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ncb1722","volume":"10","author":"PA Gregory","year":"2008","unstructured":"Gregory PA, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593\u2013601.","journal-title":"Nat Cell Biol."},{"key":"17368_CR73","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1101\/gad.1640608","volume":"22","author":"SM Park","year":"2008","unstructured":"Park SM, et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008;22:894\u2013907.","journal-title":"Genes Dev."},{"key":"17368_CR74","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/embor.2008.74","volume":"9","author":"U Burk","year":"2008","unstructured":"Burk U, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582\u20139.","journal-title":"EMBO Rep."},{"key":"17368_CR75","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.1158\/0008-5472.CAN-08-1942","volume":"68","author":"CP Bracken","year":"2008","unstructured":"Bracken CP, et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res. 2008;68:7846\u201354.","journal-title":"Cancer Res."},{"key":"17368_CR76","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.4161\/cc.7.20.6851","volume":"7","author":"PA Gregory","year":"2008","unstructured":"Gregory PA, et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008;7:3112\u20138.","journal-title":"Cell Cycle."},{"key":"17368_CR77","doi-asserted-by":"publisher","first-page":"re8","DOI":"10.1126\/scisignal.2005189","volume":"7","author":"DM Gonzalez","year":"2014","unstructured":"Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014;7:re8.","journal-title":"Sci Signal."},{"key":"17368_CR78","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1091\/mbc.e11-02-0103","volume":"22","author":"PA Gregory","year":"2011","unstructured":"Gregory PA, et al. An autocrine TGF-beta\/ZEB\/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition. Mol Biol Cell. 2011;22:1686\u201398.","journal-title":"Mol Biol Cell."},{"key":"17368_CR79","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1083\/jcb.201103097","volume":"195","author":"NH Kim","year":"2011","unstructured":"Kim NH, et al. A p53\/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J Cell Biol. 2011;195:417\u201333.","journal-title":"J Cell Biol."},{"key":"17368_CR80","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.4161\/cc.10.24.18552","volume":"10","author":"H Siemens","year":"2011","unstructured":"Siemens H, et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle. 2011;10:4256\u201371.","journal-title":"Cell Cycle."},{"key":"17368_CR81","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1172\/JCI63608","volume":"122","author":"YH Ahn","year":"2012","unstructured":"Ahn YH, et al. ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest. 2012;122:3170\u201383.","journal-title":"J Clin Invest."},{"key":"17368_CR82","doi-asserted-by":"crossref","unstructured":"Pillman KA, et al. miR-200\/375 control epithelial plasticity-associated alternative splicing by repressing the RNA-binding protein Quaking. Embo J. 2018;37(13):e99016.","DOI":"10.15252\/embj.201899016"},{"key":"17368_CR83","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/ncb1998","volume":"11","author":"U Wellner","year":"2009","unstructured":"Wellner U, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487\u201395.","journal-title":"Nat Cell Biol."},{"key":"17368_CR84","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1128\/MCB.01043-13","volume":"34","author":"XL Li","year":"2014","unstructured":"Li XL, et al. A p21-ZEB1 complex inhibits epithelial-mesenchymal transition through the microRNA 183\u201396-182 cluster. Mol Cell Biol. 2014;34:533\u201350.","journal-title":"Mol Cell Biol."},{"key":"17368_CR85","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ncb3595","volume":"19","author":"S Grelet","year":"2017","unstructured":"Grelet S, et al. A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. Nat Cell Biol. 2017;19:1105\u201315.","journal-title":"Nat Cell Biol."},{"key":"17368_CR86","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012007","volume":"97","author":"B Fan","year":"2018","unstructured":"Fan B, et al. miR-17-92 cluster is connected with disease progression and oxaliplatin\/capecitabine chemotherapy efficacy in advanced gastric cancer patients: a preliminary study. Medicine Baltimore. 2018;97:e12007.","journal-title":"Medicine Baltimore."},{"key":"17368_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.947802","volume":"13","author":"H Li","year":"2022","unstructured":"Li H, et al. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer. Front Immunol. 2022;13:947802.","journal-title":"Front Immunol."},{"key":"17368_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13203","volume":"50","author":"JH Park","year":"2020","unstructured":"Park JH, et al. Genetic variations in microRNA genes and cancer risk: a field synopsis and meta-analysis. Eur J Clin Invest. 2020;50:e13203.","journal-title":"Eur J Clin Invest."},{"key":"17368_CR89","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12885-018-4343-4","volume":"18","author":"HN Liu","year":"2018","unstructured":"Liu HN, et al. Serum microRNA signatures and metabolomics have high diagnostic value in gastric cancer. BMC Cancer. 2018;18:415.","journal-title":"BMC Cancer."},{"key":"17368_CR90","first-page":"6097","volume":"14","author":"J He","year":"2017","unstructured":"He J, et al. MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. Oncol Lett. 2017;14:6097\u2013102.","journal-title":"Oncol Lett."},{"key":"17368_CR91","doi-asserted-by":"publisher","first-page":"933","DOI":"10.7150\/ijms.82216","volume":"20","author":"H Lin","year":"2023","unstructured":"Lin H, et al. LncRNA MIR155HG overexpression promotes proliferation, migration, and chemoresistance in gastric cancer cells. Int J Med Sci. 2023;20:933\u201342.","journal-title":"Int J Med Sci."},{"key":"17368_CR92","doi-asserted-by":"publisher","first-page":"8599","DOI":"10.2147\/CMAR.S332713","volume":"13","author":"L Jin","year":"2021","unstructured":"Jin L, et al. Targeting oncogenic miR-181a-2-3p inhibits growth and suppresses cisplatin resistance of gastric cancer. Cancer Manag Res. 2021;13:8599\u2013609.","journal-title":"Cancer Manag Res."},{"key":"17368_CR93","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1177\/1535370217728460","volume":"242","author":"A Korourian","year":"2017","unstructured":"Korourian A, et al. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med Maywood. 2017;242:1842\u20137.","journal-title":"Exp Biol Med Maywood."},{"key":"17368_CR94","doi-asserted-by":"crossref","unstructured":"\u017ddralevi\u0107 M, et al. Advances in microRNAs as emerging biomarkers for colorectal cancer early detection and diagnosis. Int J Mol Sci. 2024;25(20):11060.","DOI":"10.3390\/ijms252011060"},{"key":"17368_CR95","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s13105-024-01017-y","volume":"80","author":"L Liao","year":"2024","unstructured":"Liao L, et al. MicroRNA-126 (MiR-126): key roles in related diseases. J Physiol Biochem. 2024;80:277\u201386.","journal-title":"J Physiol Biochem."},{"key":"17368_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.144025","volume":"716","author":"L Yuan","year":"2019","unstructured":"Yuan L, et al. Integrative data mining and meta-analysis to investigate the prognostic role of microRNA-200 family in various human malignant neoplasms: a consideration on heterogeneity. Gene. 2019;716:144025.","journal-title":"Gene."},{"key":"17368_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1425","volume":"13","author":"M Alahdal","year":"2023","unstructured":"Alahdal M, Elkord E. Non-coding RNAs in cancer immunotherapy: predictive biomarkers and targets. Clin Transl Med. 2023;13:e1425.","journal-title":"Clin Transl Med."},{"key":"17368_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104190","volume":"29","author":"PP Shinde","year":"2024","unstructured":"Shinde PP, Chitkara D, Mittal A. Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications. Drug Discov Today. 2024;29:104190.","journal-title":"Drug Discov Today."},{"key":"17368_CR99","doi-asserted-by":"crossref","unstructured":"Zhang L, et al. The interplay of lncRNA-H19 and its binding partners in physiological process and gastric carcinogenesis. Int J Mol Sci. 2017;18(2):450.","DOI":"10.3390\/ijms18020450"},{"key":"17368_CR100","doi-asserted-by":"publisher","first-page":"4637","DOI":"10.1038\/s41388-019-0747-0","volume":"38","author":"W He","year":"2019","unstructured":"He W, et al. MSC-regulated lncRNA MACC1-AS1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer. Oncogene. 2019;38:4637\u201354.","journal-title":"Oncogene."},{"key":"17368_CR101","doi-asserted-by":"publisher","first-page":"1257120","DOI":"10.3389\/fonc.2023.1257120","volume":"13","author":"S Bai","year":"2023","unstructured":"Bai S, Guo J, Zhang H. A meta-analysis of the clinicopathological significance of the lncRNA MALAT1 in human gastric cancer. Front Oncol. 2023;13:1257120.","journal-title":"Front Oncol."},{"key":"17368_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12687","volume":"52","author":"Q Sun","year":"2019","unstructured":"Sun Q, et al. LncRNA LOXL1-AS1 facilitates the tumorigenesis and stemness of gastric carcinoma via regulation of miR-708-5p\/USF1 pathway. Cell Prolif. 2019;52:e12687.","journal-title":"Cell Prolif."},{"key":"17368_CR103","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10142-024-01450-8","volume":"24","author":"H Elimam","year":"2024","unstructured":"Elimam H, et al. LncRNAs orchestration of gastric cancer - particular emphasis on the etiology, diagnosis, and treatment resistance. Funct Integr Genomics. 2024;24:175.","journal-title":"Funct Integr Genomics."},{"key":"17368_CR104","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14737159.2020.1842199","volume":"20","author":"E Abdi","year":"2020","unstructured":"Abdi E, et al. Emerging circulating miRNAs and lncRNAs in upper gastrointestinal cancers. Expert Rev Mol Diagn. 2020;20:1121\u201338.","journal-title":"Expert Rev Mol Diagn."},{"key":"17368_CR105","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10120-020-01096-y","volume":"24","author":"T Fu","year":"2021","unstructured":"Fu T, et al. ASB16-AS1 upregulated and phosphorylated TRIM37 to activate NF-\u03baB pathway and promote proliferation, stemness, and cisplatin resistance of gastric cancer. Gastric Cancer. 2021;24:45\u201359.","journal-title":"Gastric Cancer."},{"key":"17368_CR106","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1007\/s11033-021-06709-y","volume":"48","author":"N Dastmalchi","year":"2021","unstructured":"Dastmalchi N, et al. PVT1 and ZFAS1 lncRNAs expressions and their biomarker value in gastric cancer tissue sampling among Iranian population. Mol Biol Rep. 2021;48:7171\u20137.","journal-title":"Mol Biol Rep."},{"key":"17368_CR107","doi-asserted-by":"publisher","first-page":"963689720925059","DOI":"10.1177\/0963689720925059","volume":"29","author":"Y Hui","year":"2020","unstructured":"Hui Y, et al. LncRNA FEZF1-AS1 modulates cancer stem cell properties of human gastric cancer through miR-363-3p\/HMGA2. Cell Transplant. 2020;29:963689720925059.","journal-title":"Cell Transplant."},{"key":"17368_CR108","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.2174\/0113816128257113230921035222","volume":"29","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wen Y. The role of lncRNA NEAT1 in gastric cancer: tumor development and potential therapeutic target. Curr Pharm Des. 2023;29:2213\u201322.","journal-title":"Curr Pharm Des."},{"key":"17368_CR109","doi-asserted-by":"crossref","unstructured":"Elimam H, et al. Exploring the interplay of natural products and long non-coding RNAs in colorectal cancer: pathogenesis, diagnosis, and overcoming drug resistance. Naunyn Schmiedebergs Arch Pharmacol. 2025;398(2):1243\u20131263.","DOI":"10.1007\/s00210-024-03425-9"},{"key":"17368_CR110","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.763338","volume":"8","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, et al. A review on the role of miR-1290 in cell proliferation, apoptosis and invasion. Front Mol Biosci. 2021;8:763338.","journal-title":"Front Mol Biosci."},{"key":"17368_CR111","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12935-024-03612-x","volume":"24","author":"M Nazari","year":"2024","unstructured":"Nazari M, et al. HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives. Cancer Cell Int. 2024;24:415.","journal-title":"Cancer Cell Int."},{"key":"17368_CR112","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/cell.2016.0001","volume":"18","author":"S Wang","year":"2016","unstructured":"Wang S, et al. Long noncoding RNA ROR regulates proliferation, invasion, and stemness of gastric cancer stem cell. Cell Reprogram. 2016;18:319\u201326.","journal-title":"Cell Reprogram"},{"key":"17368_CR113","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41416-020-0836-4","volume":"122","author":"HT Liu","year":"2020","unstructured":"Liu HT, et al. LncRNA-HNF1A-AS1 functions as a competing endogenous RNA to activate PI3K\/AKT-signalling pathway by sponging miR-30b-3p in gastric cancer. Br J Cancer. 2020;122:1825\u201336.","journal-title":"Br J Cancer."},{"key":"17368_CR114","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncrna.2024.03.013","volume":"9","author":"R Giordo","year":"2024","unstructured":"Giordo R, et al. microRNA 21 and long non-coding RNAs interplays underlie cancer pathophysiology: a narrative review. Noncoding RNA Res. 2024;9:831\u201352.","journal-title":"Noncoding RNA Res."},{"key":"17368_CR115","doi-asserted-by":"crossref","unstructured":"Luo YH, et al. Circular RNA hsa_circ_0000190 facilitates the tumorigenesis and immune evasion by upregulating the expression of soluble PD-L1 in non-small cell lung cancer. Int J Mol Sci. 2021;23(1):64.","DOI":"10.3390\/ijms23010064"},{"key":"17368_CR116","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/bjc.2016.451","volume":"116","author":"P Li","year":"2017","unstructured":"Li P, et al. Circular RNA 0000096 affects cell growth and migration in gastric cancer. Br J Cancer. 2017;116:626\u201333.","journal-title":"Br J Cancer."},{"key":"17368_CR117","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3233\/CBM-170379","volume":"21","author":"H Sun","year":"2018","unstructured":"Sun H, et al. Hsa_circ_0000520, a potential new circular RNA biomarker, is involved in gastric carcinoma. Cancer Biomark. 2018;21:299\u2013306.","journal-title":"Cancer Biomark."},{"key":"17368_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154900","volume":"251","author":"M Ahmadi","year":"2023","unstructured":"Ahmadi M, Morshedzadeh F, Ghafouri-Fard S. Circular RNA_0000285: a novel double-edged sword circular RNA in human malignancies. Pathol Res Pract. 2023;251:154900.","journal-title":"Pathol Res Pract."},{"key":"17368_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23359","volume":"34","author":"Y Wang","year":"2020","unstructured":"Wang Y, et al. Novel potential tumor biomarkers: circular RNAs and exosomal circular RNAs in gastrointestinal malignancies. J Clin Lab Anal. 2020;34:e23359.","journal-title":"J Clin Lab Anal."},{"key":"17368_CR120","doi-asserted-by":"publisher","first-page":"6330","DOI":"10.3748\/wjg.v23.i34.6330","volume":"23","author":"M Huang","year":"2017","unstructured":"Huang M, et al. Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer. World J Gastroenterol. 2017;23:6330\u20138.","journal-title":"World J Gastroenterol."},{"key":"17368_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2024.155596","volume":"263","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. circ_0006089 facilitates gastric cancer progression and oxaliplatin resistance via miR-217\/NRP1. Pathol Res Pract. 2024;263:155596.","journal-title":"Pathol Res Pract."},{"key":"17368_CR122","doi-asserted-by":"publisher","first-page":"389","DOI":"10.5009\/gnl210195","volume":"17","author":"Q Liang","year":"2023","unstructured":"Liang Q, et al. circ-LDLRAD3 knockdown reduces cisplatin chemoresistance and inhibits the development of gastric cancer with cisplatin resistance through miR-588 enrichment-mediated SOX5 inhibition. Gut Liver. 2023;17:389\u2013403.","journal-title":"Gut Liver."},{"key":"17368_CR123","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1002\/jcp.31093","volume":"238","author":"Z Shang","year":"2023","unstructured":"Shang Z, et al. CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy-dependent ferroptosis. J Cell Physiol. 2023;238:2407\u201324.","journal-title":"J Cell Physiol."},{"key":"17368_CR124","first-page":"647","volume":"38","author":"C Xiang","year":"2023","unstructured":"Xiang C, et al. Circular RNA circLRCH3 promotes oxaliplatin resistance in gastric cancer through the modulation of the miR-383-5p\/FGF7 axis. Histol Histopathol. 2023;38:647\u201358.","journal-title":"Histol Histopathol."},{"key":"17368_CR125","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CAD.0000000000001391","volume":"34","author":"W Cheng","year":"2023","unstructured":"Cheng W, Luan P, Jin X. circUBAP2 inhibits cisplatin resistance in gastric cancer via miR-300\/KAT6B axis. Anticancer Drugs. 2023;34:126\u201334.","journal-title":"Anticancer Drugs."},{"key":"17368_CR126","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250603","volume":"16","author":"Z Wang","year":"2021","unstructured":"Wang Z, Liu C. Upregulated hsa_circRNA_100269 inhibits the growth and metastasis of gastric cancer through inactivating PI3K\/Akt axis. PLoS One. 2021;16:e0250603.","journal-title":"PLoS One."},{"key":"17368_CR127","doi-asserted-by":"crossref","unstructured":"Zhang X, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.","DOI":"10.3390\/ijms20225573"},{"key":"17368_CR128","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, et al. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"17368_CR129","doi-asserted-by":"crossref","unstructured":"N\u00fa\u00f1ez-Mart\u00ednez HN, Recillas-Targa F. Emerging functions of lncRNA loci beyond the transcript itself. Int J Mol Sci. 2022;23(11):6258.","DOI":"10.3390\/ijms23116258"},{"key":"17368_CR130","first-page":"1051","volume":"11","author":"J Yue","year":"2021","unstructured":"Yue J, et al. LncRNAs link cancer stemness to therapy resistance. Am J Cancer Res. 2021;11:1051\u201368.","journal-title":"Am J Cancer Res."},{"key":"17368_CR131","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1186\/s12885-023-11164-y","volume":"23","author":"M Yang","year":"2023","unstructured":"Yang M, et al. Six polymorphisms in the lncRNA H19 gene and the risk of cancer: a systematic review and meta-analysis. BMC Cancer. 2023;23:688.","journal-title":"BMC Cancer."},{"key":"17368_CR132","doi-asserted-by":"publisher","first-page":"17181","DOI":"10.1038\/s41598-023-43744-0","volume":"13","author":"S Chen","year":"2023","unstructured":"Chen S, et al. H19 encourages aerobic glycolysis and cell growth in gastric cancer cells through the axis of microRNA-19a-3p and phosphoglycerate kinase 1. Sci Rep. 2023;13:17181.","journal-title":"Sci Rep."},{"key":"17368_CR133","doi-asserted-by":"publisher","first-page":"14185","DOI":"10.1038\/s41598-024-65221-y","volume":"14","author":"X He","year":"2024","unstructured":"He X, et al. A prominent role of lncRNA H19 in H. pylori CagA-induced DNA damage response and cell malignancy. Sci Rep. 2024;14:14185.","journal-title":"Sci Rep."},{"key":"17368_CR134","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.18632\/oncotarget.1913","volume":"5","author":"H Li","year":"2014","unstructured":"Li H, et al. Overexpression of lncRNA H19 enhances carcinogenesis and metastasis of gastric cancer. Oncotarget. 2014;5:2318\u201329.","journal-title":"Oncotarget."},{"key":"17368_CR135","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1159\/000518627","volume":"40","author":"J Liu","year":"2022","unstructured":"Liu J, et al. LncRNA H19 promoted the epithelial-to-mesenchymal transition and metastasis in gastric cancer via activating Wnt\/\u03b2-catenin-signaling. Dig Dis. 2022;40:436\u201347.","journal-title":"Dig Dis."},{"key":"17368_CR136","doi-asserted-by":"publisher","first-page":"8800","DOI":"10.2174\/0929867328666210521213352","volume":"28","author":"W Xu","year":"2021","unstructured":"Xu W, et al. Molecular mechanism of the canonical oncogenic lncRNA MALAT1 in gastric cancer. Curr Med Chem. 2021;28:8800\u20139.","journal-title":"Curr Med Chem."},{"key":"17368_CR137","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/0092-8674(76)90223-3","volume":"8","author":"D Kolakofsky","year":"1976","unstructured":"Kolakofsky D. Isolation and characterization of Sendai virus DI-RNAs. Cell. 1976;8:547\u201355.","journal-title":"Cell."},{"key":"17368_CR138","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.jmb.2015.02.018","volume":"427","author":"S Kelly","year":"2015","unstructured":"Kelly S, et al. Exon skipping is correlated with exon circularization. J Mol Biol. 2015;427:2414\u20137.","journal-title":"J Mol Biol."},{"key":"17368_CR139","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","volume":"20","author":"LS Kristensen","year":"2019","unstructured":"Kristensen LS, et al. The biogenesis, biology, and characterization of circular RNAs. Nat Rev Genet. 2019;20:675\u201391.","journal-title":"Nat Rev Genet."},{"key":"17368_CR140","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1261\/rna.035667.112","volume":"19","author":"WR Jeck","year":"2013","unstructured":"Jeck WR, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 2013;19:141\u201357.","journal-title":"RNA."},{"key":"17368_CR141","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1093\/nar\/gkz311","volume":"47","author":"CA Schmidt","year":"2019","unstructured":"Schmidt CA, et al. Molecular determinants of metazoan tricRNA biogenesis. Nucleic Acids Res. 2019;47:6452\u201365.","journal-title":"Nucleic Acids Res."},{"key":"17368_CR142","doi-asserted-by":"publisher","first-page":"1182900","DOI":"10.3389\/fcell.2023.1182900","volume":"11","author":"H Xiong","year":"2023","unstructured":"Xiong H, et al. Circ-SHPRH in human cancers: a systematic review and meta-analysis. Front Cell Dev Biol. 2023;11:1182900.","journal-title":"Front Cell Dev Biol."},{"key":"17368_CR143","doi-asserted-by":"publisher","first-page":"1097956","DOI":"10.3389\/fonc.2023.1097956","volume":"13","author":"K Sun","year":"2023","unstructured":"Sun K, et al. Emerging landscape of circFNDC3B and its role in human malignancies. Front Oncol. 2023;13:1097956.","journal-title":"Front Oncol."},{"key":"17368_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154588","volume":"248","author":"S Khalilian","year":"2023","unstructured":"Khalilian S, et al. circGFRA1: a circular RNA with important roles in human carcinogenesis. Pathol Res Pract. 2023;248:154588.","journal-title":"Pathol Res Pract."},{"key":"17368_CR145","doi-asserted-by":"publisher","first-page":"1061007","DOI":"10.3389\/fonc.2022.1061007","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang X, et al. CircCCDC66: emerging roles and potential clinical values in malignant tumors. Front Oncol. 2022;12:1061007.","journal-title":"Front Oncol."},{"key":"17368_CR146","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12967-024-05001-4","volume":"22","author":"Q Ma","year":"2024","unstructured":"Ma Q, et al. Emerging roles of circular RNAs in tumorigenesis, progression, and treatment of gastric cancer. J Transl Med. 2024;22:207.","journal-title":"J Transl Med."},{"key":"17368_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1093","volume":"8","author":"X Cai","year":"2020","unstructured":"Cai X, et al. Circ_0000267 promotes gastric cancer progression via sponging MiR-503-5p and regulating HMGA2 expression. Mol Genet Genomic Med. 2020;8:e1093.","journal-title":"Mol Genet Genomic Med."},{"key":"17368_CR148","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202200957RR","volume":"36","author":"C Li","year":"2022","unstructured":"Li C, et al. circBGN accelerates gastric cancer cell proliferation and invasion via activating IL6\/STAT3 signaling pathway. Faseb J. 2022;36:e22604.","journal-title":"Faseb J."},{"key":"17368_CR149","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12943-020-01208-3","volume":"19","author":"M Xie","year":"2020","unstructured":"Xie M, et al. Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p\/HUR\/VEGF axis and suppressing HSP90 degradation. Mol Cancer. 2020;19:112.","journal-title":"Mol Cancer."},{"key":"17368_CR150","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2019.11.038","volume":"471","author":"J Lu","year":"2020","unstructured":"Lu J, et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 2020;471:38\u201348.","journal-title":"Cancer Lett."},{"key":"17368_CR151","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.omto.2021.11.002","volume":"23","author":"X Liang","year":"2021","unstructured":"Liang X, et al. Circular RNA circRAB31 acts as a miR-885-5psponge to suppress gastric cancer progressionvia the PTEN\/PI3K\/AKT pathway. Mol Ther Oncolytics. 2021;23:501\u201314.","journal-title":"Mol Ther Oncolytics."},{"key":"17368_CR152","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12943-024-02084-x","volume":"23","author":"X Yu","year":"2024","unstructured":"Yu X, et al. The role of microRNAs in the gastric cancer tumor microenvironment. Mol Cancer. 2024;23:170.","journal-title":"Mol Cancer."},{"key":"17368_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188908","volume":"1878","author":"A Mishra","year":"2023","unstructured":"Mishra A, et al. A tale of exosomes and their implication in cancer. Biochim Biophys Acta Rev Cancer. 2023;1878:188908.","journal-title":"Biochim Biophys Acta Rev Cancer."},{"key":"17368_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121949","volume":"293","author":"FU Rehman","year":"2023","unstructured":"Rehman FU, et al. Exosomes-based strategies for brain drug delivery. Biomaterials. 2023;293:121949.","journal-title":"Biomaterials."},{"key":"17368_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e32376","volume":"10","author":"M Wang","year":"2024","unstructured":"Wang M, Jin F, Tong X. From bench to bedside: the promising value of exosomes in precision medicine for CNS tumors. Heliyon. 2024;10:e32376.","journal-title":"Heliyon."},{"key":"17368_CR156","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1111\/cas.13697","volume":"109","author":"YL Tai","year":"2018","unstructured":"Tai YL, et al. Exosomes in cancer development and clinical applications. Cancer Sci. 2018;109:2364\u201374.","journal-title":"Cancer Sci."},{"key":"17368_CR157","doi-asserted-by":"crossref","unstructured":"Li T, et al. The therapeutic potential and clinical significance of exosomes as carriers of drug delivery system. Pharmaceutics. 2022;15(1):21.","DOI":"10.3390\/pharmaceutics15010021"},{"key":"17368_CR158","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12943-021-01396-6","volume":"20","author":"XH Tang","year":"2021","unstructured":"Tang XH, et al. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. 2021;20:99.","journal-title":"Mol Cancer."},{"key":"17368_CR159","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s13277-014-2807-y","volume":"36","author":"Q Li","year":"2015","unstructured":"Li Q, et al. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol. 2015;36:2007\u201312.","journal-title":"Tumour Biol."},{"key":"17368_CR160","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1158\/1055-9965.EPI-16-0607","volume":"26","author":"Z Huang","year":"2017","unstructured":"Huang Z, et al. Six Serum-based miRNAs as potential diagnostic biomarkers for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:188\u201396.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"17368_CR161","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/mc.22838","volume":"57","author":"H Yang","year":"2018","unstructured":"Yang H, et al. Exosomal miR-423-5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer. Mol Carcinog. 2018;57:1223\u201336.","journal-title":"Mol Carcinog."},{"key":"17368_CR162","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/jamasurg.2020.1133","volume":"155","author":"X Guo","year":"2020","unstructured":"Guo X, et al. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a biomarker for early detection and monitoring progression of gastric cancer: a multiphase study. JAMA Surg. 2020;155:572\u20139.","journal-title":"JAMA Surg."},{"key":"17368_CR163","first-page":"1081","volume":"43","author":"H Ohzawa","year":"2020","unstructured":"Ohzawa H, et al. Reduced expression of exosomal miR-29s in peritoneal fluid is a useful predictor of peritoneal recurrence after curative resection of gastric cancer with serosal involvement. Oncol Rep. 2020;43:1081\u20138.","journal-title":"Oncol Rep."},{"key":"17368_CR164","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1080\/15384101.2022.2087280","volume":"21","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. circFCHO2 promotes gastric cancer progression by activating the JAK1\/STAT3 pathway via sponging miR-194-5p. Cell Cycle. 2022;21:2145\u201364.","journal-title":"Cell Cycle."},{"key":"17368_CR165","first-page":"319","volume":"40","author":"Y Kumata","year":"2018","unstructured":"Kumata Y, et al. Exosome-encapsulated microRNA-23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage. Oncol Rep. 2018;40:319\u201330.","journal-title":"Oncol Rep."},{"key":"17368_CR166","doi-asserted-by":"publisher","first-page":"630","DOI":"10.4251\/wjgo.v16.i3.630","volume":"16","author":"XL Guan","year":"2024","unstructured":"Guan XL, Guan XY, Zhang ZY. Roles and application of exosomes in the development, diagnosis, and treatment of gastric cancer. World J Gastrointest Oncol. 2024;16:630\u201342.","journal-title":"World J Gastrointest Oncol."},{"key":"17368_CR167","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-022-01671-0","volume":"21","author":"QF Han","year":"2022","unstructured":"Han QF, et al. Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer. Mol Cancer. 2022;21:207.","journal-title":"Mol Cancer."},{"key":"17368_CR168","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1002\/jcb.27813","volume":"120","author":"K Jiang","year":"2019","unstructured":"Jiang K, et al. The critical role of exosomes in tumor biology. J Cell Biochem. 2019;120:6820\u201332.","journal-title":"J Cell Biochem."},{"key":"17368_CR169","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.ymthe.2018.01.001","volume":"26","author":"X Wang","year":"2018","unstructured":"Wang X, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther. 2018;26:774\u201383.","journal-title":"Mol Ther."},{"key":"17368_CR170","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12967-022-03527-z","volume":"20","author":"Z Guo","year":"2022","unstructured":"Guo Z, et al. Engineered exosome-mediated delivery of circDIDO1 inhibits gastric cancer progression via regulation of MiR-1307-3p\/SOCS2 axis. J Transl Med. 2022;20:326.","journal-title":"J Transl Med."},{"key":"17368_CR171","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.7150\/thno.97755","volume":"14","author":"EH Kim","year":"2024","unstructured":"Kim EH, et al. Targeted delivery of anti-miRNA21 sensitizes PD-L1(high) tumor to immunotherapy by promoting immunogenic cell death. Theranostics. 2024;14:3777\u201392.","journal-title":"Theranostics."},{"key":"17368_CR172","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.2147\/IJN.S231214","volume":"15","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, et al. Exosome-delivered c-Met siRNA could reverse chemoresistance to cisplatin in gastric cancer. Int J Nanomed. 2020;15:2323\u201335.","journal-title":"Int J Nanomed."},{"key":"17368_CR173","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.cell.2019.02.029","volume":"177","author":"DK Jeppesen","year":"2019","unstructured":"Jeppesen DK, et al. Reassessment of exosome composition. Cell. 2019;177:428-445.e18.","journal-title":"Cell."},{"key":"17368_CR174","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.cmet.2021.08.006","volume":"33","author":"R Isaac","year":"2021","unstructured":"Isaac R, et al. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. 2021;33:1744\u201362.","journal-title":"Cell Metab."},{"key":"17368_CR175","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, et al. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9:274.","journal-title":"Signal Transduct Target Ther."},{"key":"17368_CR176","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.2147\/IJN.S207589","volume":"14","author":"J Ye","year":"2019","unstructured":"Ye J, et al. Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages. Int J Nanomed. 2019;14:3203\u201320.","journal-title":"Int J Nanomed."},{"key":"17368_CR177","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1021\/acs.molpharmaceut.3c01158","volume":"21","author":"F Guo","year":"2024","unstructured":"Guo F, et al. Recent progress of small interfering RNA delivery on the market and clinical stage. Mol Pharm. 2024;21:2081\u201396.","journal-title":"Mol Pharm."},{"key":"17368_CR178","doi-asserted-by":"crossref","unstructured":"Mousazadeh H, et al. Cyclodextrin-based natural nanostructured carbohydrate polymers as effective non-viral siRNA delivery systems for cancer gene therapy. J Controlled Release. 2020;330:1046-1070.","DOI":"10.1016\/j.jconrel.2020.11.011"},{"key":"17368_CR179","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30:1\u20139.","journal-title":"Amyloid."},{"key":"17368_CR180","doi-asserted-by":"crossref","unstructured":"Tani H. Recent advances and prospects in RNA drug development. Int J Mol Sci. 2024;25(22):12284.","DOI":"10.3390\/ijms252212284"},{"key":"17368_CR181","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molmed.2023.10.005","volume":"30","author":"S Guo","year":"2024","unstructured":"Guo S, Zhang M, Huang Y. Three, \u201cE\u201d challenges for siRNA drug development. Trends Mol Med. 2024;30:13\u201324.","journal-title":"Trends Mol Med."},{"key":"17368_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107102","volume":"201","author":"MD P\u00e9rez-Carri\u00f3n","year":"2024","unstructured":"P\u00e9rez-Carri\u00f3n MD, Posadas I, Ce\u00f1a V. Nanoparticles and siRNA: a new era in therapeutics? Pharmacol Res. 2024;201:107102.","journal-title":"Pharmacol Res."},{"key":"17368_CR183","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115927","volume":"169","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, et al. Advances in RNAi therapies for gastric cancer: targeting drug resistance and nanoscale delivery. Biomed Pharmacother. 2023;169:115927.","journal-title":"Biomed Pharmacother."},{"key":"17368_CR184","doi-asserted-by":"crossref","unstructured":"Rhim J, et al. From molecular mechanisms to therapeutics: understanding microRNA-21 in cancer. Cells. 2022;11(18):2791.","DOI":"10.3390\/cells11182791"},{"key":"17368_CR185","doi-asserted-by":"crossref","unstructured":"Zhang C, et al. Overview of microRNAs as diagnostic and prognostic biomarkers for high-incidence cancers in 2021. Int J Mol Sci. 2022;23(19):11389.","DOI":"10.3390\/ijms231911389"},{"key":"17368_CR186","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10238-023-01260-5","volume":"24","author":"A Zabeti Touchaei","year":"2024","unstructured":"Zabeti Touchaei A, Vahidi S, Samadani AA. Decoding the regulatory landscape of lncRNAs as potential diagnostic and prognostic biomarkers for gastric and colorectal cancers. Clin Exp Med. 2024;24:29.","journal-title":"Clin Exp Med."},{"key":"17368_CR187","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12951-024-02760-6","volume":"22","author":"Y Fei","year":"2024","unstructured":"Fei Y, et al. Circ_0008315 promotes tumorigenesis and cisplatin resistance and acts as a nanotherapeutic target in gastric cancer. J Nanobiotechnol. 2024;22:519.","journal-title":"J Nanobiotechnol."},{"key":"17368_CR188","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23918","volume":"36","author":"C Chang","year":"2022","unstructured":"Chang C, et al. Circular RNA mitochondrial translation optimization 1 correlates with less lymph node metastasis, longer disease-free survival, and higher chemotherapy sensitivity in gastric cancer. J Clin Lab Anal. 2022;36:e23918.","journal-title":"J Clin Lab Anal."},{"key":"17368_CR189","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-020-01185-7","volume":"19","author":"L Wei","year":"2020","unstructured":"Wei L, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Molecular Cancer. 2020;19:62.","journal-title":"Molecular Cancer."},{"key":"17368_CR190","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.2147\/CMAR.S243796","volume":"12","author":"Q Dai","year":"2020","unstructured":"Dai Q, Zhang T, Li C. LncRNA MALAT1 regulates the cell proliferation and cisplatin resistance in gastric cancer via PI3K\/AKT pathway. Cancer Manag Res. 2020;12:1929\u201339.","journal-title":"Cancer Manag Res."},{"key":"17368_CR191","first-page":"1607","volume":"18","author":"X Wei","year":"2019","unstructured":"Wei X, et al. MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein. Oncol Lett. 2019;18:1607\u201316.","journal-title":"Oncol Lett."},{"key":"17368_CR192","doi-asserted-by":"crossref","unstructured":"Janiczek-Polewska M, et al. Diagnostic potential of miR-143-5p, miR-143-3p, miR-551b-5p, and miR-574-3p in chemoresistance of locally advanced gastric cancer: a preliminary study. Int J Mol Sci. 2024;25(15):8057.","DOI":"10.3390\/ijms25158057"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17368-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T13:59:36Z","timestamp":1751464776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":192,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["17368"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17368-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}